Aclaris Therapeutics

Aclaris Therapeutics ACRS Stock

$3.44   -4.438282%
Add to favorites
Market Cap
$551.18M
LOW - HIGH [24H]
$3.34 - $3.56
VOLUME [24H]
$1.56M
P/E Ratio
0
Earnings per share
-$0.59
ISIN
US00461U1051
Price   Prediction

Aclaris Therapeutics Price Chart

Sorry, that's all we've gotfor now...

Aclaris Therapeutics (ACRS) stock price today is 3.45 USD on Tech Market Large (-4.44% on the day). Updated .

Aclaris Therapeutics ACRS Financial and Trading Overview

Aclaris Therapeutics stock price 3.45 USD
Previous Close 3.92 USD
Open 3.31 USD
Bid 2.65 USD x 200
Ask 3.61 USD x 100
Day's Range 3.31 - 3.7 USD
52 Week Range 2.34 - 6.6 USD
Volume 9.95M USD
Avg. Volume 2.9M USD
Market Cap 571.8M USD
Beta (5Y Monthly) 0.936
PE Ratio (TTM) N/A
EPS (TTM) -0.59 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 10.27 USD

ACRS Valuation Measures

Enterprise Value 459.21M USD
Trailing P/E N/A
Forward P/E -5.2177563
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 89.32929
Price/Book (mrq) 3.2594938
Enterprise Value/Revenue 71.741
Enterprise Value/EBITDA N/A

Trading Information

Aclaris Therapeutics Stock Price History

Beta (5Y Monthly) 0.936
52-Week Change 60.00%
S&P500 52-Week Change 13.32%
52 Week High 6.6 USD
52 Week Low 2.34 USD
50-Day Moving Average 4.43 USD
200-Day Moving Average 4.54 USD

ACRS Share Statistics

Avg. Volume (3 month) 2.9M USD
Avg. Daily Volume (10-Days) 1.99M USD
Shares Outstanding 158.61M
Float 113.65M
Short Ratio 2.92
% Held by Insiders 2.31%
% Held by Institutions 83.48%
Shares Short 11.57M
Short % of Float 8.19%
Short % of Shares Outstanding 7.29%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio N/A
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 0%
Operating Margin (ttm) -1412.40%
Gross Margin 0%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -28.85%
Return on Equity (ttm) -55.51%

Income Statement

Revenue (ttm) 6.4M USD
Revenue Per Share (ttm) 0.05 USD
Quarterly Revenue Growth (yoy) -55.10%
Gross Profit (ttm) -66003000 USD
EBITDA N/A
Net Income Avi to Common (ttm) -79634000 USD
Diluted EPS (ttm) -0.54
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 114.29M USD
Total Cash Per Share (mrq) 0.72 USD
Total Debt (mrq) 1.71M USD
Total Debt/Equity (mrq) 1.03 USD
Current Ratio (mrq) 5.088
Book Value Per Share (mrq) 1.106

Cash Flow Statement

Operating Cash Flow (ttm) -75207000 USD
Levered Free Cash Flow (ttm) -50129000 USD

Profile of Aclaris Therapeutics

Country United States
State PA
City Wayne
Address 701 Lee Road
ZIP 19087
Phone 484 324 7933
Website https://www.aclaristx.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 69

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Q&A For Aclaris Therapeutics Stock

What is a current ACRS stock price?

Aclaris Therapeutics ACRS stock price today per share is 3.45 USD.

How to purchase Aclaris Therapeutics stock?

You can buy ACRS shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Aclaris Therapeutics?

The stock symbol or ticker of Aclaris Therapeutics is ACRS.

Which industry does the Aclaris Therapeutics company belong to?

The Aclaris Therapeutics industry is Biotechnology.

How many shares does Aclaris Therapeutics have in circulation?

The max supply of Aclaris Therapeutics shares is 159.99M.

What is Aclaris Therapeutics Price to Earnings Ratio (PE Ratio)?

Aclaris Therapeutics PE Ratio is now.

What was Aclaris Therapeutics earnings per share over the trailing 12 months (TTM)?

Aclaris Therapeutics EPS is -0.59 USD over the trailing 12 months.

Which sector does the Aclaris Therapeutics company belong to?

The Aclaris Therapeutics sector is Healthcare.

Aclaris Therapeutics ACRS included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 24228.79 USD —
-1.15
5.28B USD — 23989.09 USD — 24547.66 USD — — 5.28B USD —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
us US Tech Global Select Market Com NQGS US 11932.06 USD —
-1.16
— — 11815.78 USD — 12090.12 USD — — — —
us US Tech Biotechnology NBI US 7020.35 USD —
-0.68
— — 6949.3 USD — 7058.02 USD — — — —
us US Tech Health Care IXHC US 1334.51 USD —
-0.61
— — 1323.81 USD — 1342.94 USD — — — —
us US Tech Composite Total Return XCMP US 29940 USD —
-1.15
— — 29644.9 USD — 30335.16 USD — — — —
$2.19T
Total marketcap
$77.77B
Total volume
BTC 58.35%   •   ETH 9.95%
Dominance
Select currency